Pain Management Devices Market

Market Overview

The total addressable market (TAM) for pain management devices was valued at USD 6.38 billion in 2021. It is estimated to reach USD 13.97 billion by 2030, growing at a CAGR of 9.1% during the forecast period (2022–2030).

Pain management is a medical specialty to reduce the suffering of people with persistent pain. Pain management devices are different medical devices used to manage different kinds of chronic pain, such as neuropathic pain, cancer pain, musculoskeletal pain, nociceptive pain, and others. Infusion pumps for painkillers, spinal cord stimulators, neurostimulators, and ablation devices are just a few of the many pain management devices available on the market. The rise in the geriatric population, the rise in consumer awareness of pain management devices, the rise in chronic pain, the introduction of novel products, and increased research and development (R&D) will all propel the growth of the global pain management devices market.

Market Dynamics

Market Driving Factors

Increasing Global Prevalence of Chronic Diseases and Geriatric Population

The rise in chronic diseases is one of the main factors expected to propel the pain management device market expansion in the coming years. Demand for muscle and nerve stimulators has increased because diseases like diabetes and obesity are becoming more common because of how people live. According to the International Diabetes Federation, in 2017, around 72.946.4 cases of diabetes were reported in India. According to the WHO, diabetes poses a severe problem in India, where 8.7% of the population is affected. One of the primary uses of electrical stimulators is to treat neuropathy, which affects people with diabetes frequently.

Additionally, the increase in cancer prevalence has further propelled the demand for pain management devices to help reduce the pain from nerve compression caused by the tumor and other variables depending on the cancer's progression. The medications offered to patients are also a possible contributor to managing pain. Studies also indicate that at the time of diagnosis, about 20% to 50% of cancer patients feel acute pain, and about 75% complain of pain as the disease progresses. Such factors are anticipated to boost the market.

Musculoskeletal disorders like arthritis, osteoarthritis, orthopedic degenerative disorders, and rheumatoid arthritis are becoming more common. This has augmented the prevalence of chronic pain among these individuals and their inability to carry out routine tasks. Furthermore, aging is considered a significant risk factor for chronic conditions. The geriatric population is highly susceptible to chronic conditions such as diabetes, cardiovascular disorders, and cancer. Therefore, the market for pain management devices is likely to grow faster due to the increasing number of elderly people worldwide. Currently, about 46 million people in the U.S. belong to the age group of 65 and above, and this number is expected to reach 98 million by 2060. According to the WHO, the percentage of the geriatric population is expected to reach 22% in 2050 from 12% in 2015.

Ineffectiveness of Oral Drugs and Low Preference for Surgical Intervention

People are turning to pain management devices like those found in hospitals because oral medications have failed to relieve pain. Painkillers are a common addiction but can also have unwanted side effects and be ineffective. According to a study published in Practical Pain Management, 14% of patients who were given codeine felt less pain. In addition, researchers stated that there was no magic bullet for relieving patients' pain.

Low preference for surgeries is one of the factors boosting the demand for pain management devices. Several patients tend to avoid surgery if alternative treatments are available. This can be attributed to the prevalence of Surgical Site Infections (SSI). According to NNIS data, CDC, SSIs are the 3rd most commonly reported nosocomial infection; they may result in morbidity and risk a patient's life, increasing the duration of stay and overall healthcare costs.

Market Restraining Factors

Adverse Effects Associated with Devices

The possible adverse effects of pain management devices can be a crucial market restraint over the coming years. Some patients experience uncomfortable prickling, buzzing, or tingling sensations caused by the electric impulses produced by the TENS unit. Due to the adhesive pads on devices, certain patients experience allergies, such as skin rashes, redness, and irritation.

Several adverse effects are also reported when the electrodes are placed on the front of the eyes or the neck. For instance, electrodes placed on the neck tend to cause spasms by lowering blood pressure. Electrodes placed on the eyes can lead to injury due to increased ocular pressure. Such factors are anticipated to limit the market over the forecast period.

Key Market Opportunities

Favorable Reimbursement Policies

Favorable reimbursement policies are expected to create tremendous opportunities for the pain management devices market over the forecast period. In North America, Medicare covers the costs of medical devices by reimbursing providers when the device is in use. Medicare adds the average cost to the total payment rates for services. In Europe, device reimbursement and coverage are handled by the publicly funded NHS. Additionally, such systems cover roughly four-fifths of the population in France, the United Kingdom, Germany, and Italy. Marketing authorization of a device in one nation should provide access to different markets through the Conformité Européenne marking process, which indicates the device's safety and function as intended.

In Asia, patients in low and middle-income countries receive minimal or no reimbursement for medical devices. However, in Japan, the Ministry of Health, Labour, and Welfare governs the regulatory framework for medical devices. Its main objectives are to reduce clinical trial costs and offer patients and companies benefits. In Argentina, the Compulsory Medical Program, Programa Médico Obligatorio (PMO), takes care of the reimbursement for medical devices and care services. PMO coverage.

Segmental Analysis

The global pain management devices market is segmented by product and application.

By product, the global pain management devices market is divided into electrical stimulators, radiofrequency ablation, analgesic infusion pumps, and neurostimulation.

The neurostimulation segment is the highest contributor to the market and is expected to grow at a CAGR of 9.3% during the forecast period. Neurostimulation is becoming more popular because neurological disorders are becoming more common. These neurostimulators are very important for treating depression, Parkinson's disease, epilepsy, and movement disorders. Neurostimulators send electrical signals to certain parts of the brain, spinal cord, and nervous system to help treat neurological conditions. In addition, factors such as escalating product demand, the introduction of technologically advanced products, and a growing geriatric population are anticipated to drive the market. Moreover, add-on therapy, an increase in the incidence of chronic diseases, such as epilepsy and migraine, and unmet medical needs in these disease segments are boosting the market growth.

The growth of the analgesic infusion pump segment can be attributed to the growing demand for analgesic drugs to treat chronic pain, such as that caused by myocardial infarction, complex pain syndrome, failed back syndrome, and pain after surgery. These pumps treat certain neurological conditions, such as cerebral palsy and spinal cord injuries. Thus, the prevalence of these diseases is anticipated to drive segment growth.

By application, the global pain management devices market is divided into cancer, neuropathic pain, facial and migraine, musculoskeletal disorder, and trauma.

The neuropathic pain segment owns the highest market share and is expected to grow at a 9.5% CAGR during the forecast period. Pain management devices are widely used to treat neuropathic conditions. It is a chronic pain condition caused by progressive chronic nerve disease and can also occur due to an infection, an injury, or the loss of a limb. Devices designed to alleviate the suffering of those who suffer from chronic pain due to conditions like neuropathic pain are a necessity. Furthermore, neuropathic pain is known to get worse as time passes. The prevalence of neuropathic pain is anticipated to boost market growth. According to the CDC, 65% of people in the U.S. aged 65 and above suffer from chronic pain.

The growing number of cancer cases has increased the demand for pain management devices to reduce the pain caused due to nerve compression, mainly because of tumor compression and other variables depending upon the cancer’s progression. The medications offered to patients are also a possible contributor to the pain. Studies show that between 20% and 50% of people with cancer feel severe pain when they are first diagnosed and that about 75% of people with cancer complain of pain as the disease worsens.

Regional Analysis

North America Dominates the Global Market

By region, the global pain management devices market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America is the most significant shareholder in the global pain management devices market and is expected to grow at a CAGR of 7.5% during the forecast period. The presence of significant market participants, such as Baxter International, Boston Scientific Corporation, Johnson & Johnson, Inc., DJO Global LLC, Pfizer, Inc., Smiths Medical, Inc., Abbott, and Stryker Corporation, strengthens the North American market. Increasing adoption of pain management devices due to favorable reimbursement scenarios, such as health insurance provided by the Centers for Medicare and Medicaid Services, has also driven the market in this region. Additionally, an increase in disposable income is expected to result in the adoption of technologically advanced pain management devices. Growing demand for drug-free therapies is likely to boost the adoption rate of pain management devices.

Europe is expected to grow at a CAGR of 7.2% over the forecast period. The presence of market players such as B. Braun Melsungen AG and Medtronic is expected to boost market growth. Increasing awareness regarding chronic pain disorders and pain management devices for treatment is expected to propel market growth. For instance, European Medicines Agency conducted awareness sessions in December 2019 to create awareness regarding medical devices among medical device regulators. In addition, the growing adoption of digitalization strategies in countries such as Germany helps lower device procurement costs. These strategies include the DiGA fast track launched in May 2020 at the Federal Institute for Drugs and Medical Devices (BfArM). The initiative offers a structured path for digital healthcare solutions to be qualified for reimbursement. Increasing investments in countries such as the Czech Republic, Bulgaria, Poland, Croatia, and Russia are high-potential markets in Europe.

Asia-Pacific is expected to grow significantly over the forecast period. The presence of significant market participants, such as Omron Healthcare (Japan), strengthens the market. In addition, the Ministry of Health, Labour, and Welfare, Japan, governs the regulatory framework for medical devices to reduce the cost of clinical trials and offer benefits to patients and companies. Increasing adoption of pain management devices due to growing awareness is expected to boost regional growth. Low-cost manufacturing in countries of Asia-Pacific, such as China and India, has caused manufacturers to outsource their manufacturing activities to contract manufacturers in these countries.

Additionally, the increasing geriatric population, especially in Japan, strengthens the market, as elderly people are more susceptible to chronic pain and require medical attention. Growing disposable income is expected to increase the adoption of technologically advanced pain management devices. Rising investments by market players to develop intrathecal infusion pumps and other technologically advanced pain management devices create growth opportunities in the market.

Recent Developments

• December 2022- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced a recent retrospective study published in the Journal of Clinical Medicine Special Issue "Advances in Postoperative Pain Management and Postoperative Chronic Pain".